Viking Therapeutics Inc (VKTX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket
 


Viking Therapeutics Inc   (NASDAQ: VKTX)


Viking Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Viking Therapeutics Inc's ROI in the third quarter of 2026?
Viking Therapeutics Inc recorded a cumulative net loss of $-627 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -104.69%.

Within the Healthcare sector 617 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 3805 to 3911.

Definition and Formula of Return on Investment



Return On Investment (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM -25.96 % -34.03 % -25.59 % -17.86 % 3.92 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 843 412 502 639 713
Return On Investment (TTM) -104.69 % -94.39 % -71.31 % -48.02 % -29.34 %
VKTX's Overall Ranking # 3911 # 3805 # 3351 # 3258 #
Seq. Investment Change TTM 5.75 % -14.46 % -11.55 % -7.45 % -5.78 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -627 -535 -472 -360 -237




Return On Investment VKTX's Ranking
Within: No.
Industry # 278
Sector # 618
Overall # 3911

Return On Investment Statistics
High Average Low
-8.09 %
-66.39 %
-487.43 %
(Sep 30 2019)   (Dec 31 2015)







Financial Statements
Viking Therapeutics Inc's III. Quarter Investments $ 843 Millions VKTX's Balance sheet
Viking Therapeutics Inc's III. Quarter Income $ -183 Millions Quarterly VKTX's Income Statement
VKTX's Income by Division See VKTX's Income by Division


VKTX Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 639 880 348 145 202
Y / Y Investment Growth -27.4 % 152.65 % 139.76 % -28.02 % -17.38 %
Net Income in Millions -360 -110 -86 -69 -55
Y / Y Net Income Growth - - - - -
Annual Return On Investment -56.28 % -12.49 % -24.65 % -47.39 % -27.24 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VKTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VKTX's Competitors
Subscribers only: Roi for Viking Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for VKTX's Customers

Other Ratios
VKTX's Roa VKTX's Inventory Turnover Ratio VKTX's Growth Rates VKTX's Dividend Statistics
VKTX's Profitability Ratios VKTX's Asset Turnover Ratio VKTX's Dividend Growth
VKTX's Roe VKTX's Valuation Ratios VKTX's Financial Strength Ratios VKTX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI


Date modified: 2026-10-30T13:26:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.